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Abstract
Background: With the advent of newer and safer fluids there have been numerous trials
and studies conducted to test the safety and validity of colloids. Are colloids more effective then
crystalloid for emergent resuscitation? The purpose of this systematic literature review is to
assess the claims on treatment success and explore safety to gain clarity on which fluid is the
best treatment for the patient.
Methods: A systematic database search was conducted from 2006 to the present. The
search utilized such sources as PubMed, UpToDate and ScienceDirect. This search included
more than 70 journal articles, where 24 articles were selected for review for their credibility and
usage within the medical community.
Results: Considering the reviewed articles, it seems that the benefits may not outweigh
the risks inherent with colloids. In summary, using colloids as an alternative to crystalloids made
little to no difference in the cause of mortality. However, there was evidence that colloids can
increase the need for renal therapies overall.
Conclusion: Colloids were merely marginal, if at all, more effective than crystalloids in
reducing the mortality rates, but with the added risk of renal dysfunction. There are instances
where colloids might be selected, but those occurrences should be critically challenged. In the
end, it appears to be left up to clinical judgement, provider experience, and accessibility on
which fluid selection is optimal.
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Introduction
Acute care settings are designed to treat the critically ill and injured. Providers in these
settings rely on IV fluids for resuscitation of critically ill or injured patients. The goal of this
paper is to evaluate the effectiveness of IV fluids to determine if colloids are more effective than
crystalloids in the resuscitation of critically ill adults. The different fluids will be evaluated in the
setting of sepsis, acute fluid resuscitation in the ICU, hypovolemia, to include hemorrhagic
shock, and burns patients. The outcome measures will be mortality of these critically ill patients.
Hemorrhage is responsible for 30 40% of trauma mortality with 33 56% of these deaths
occurring during the prehospital period.1 Patients that do reach critical care in time to receive
treatment, mortality can be caused by continued hemorrhage, shock, sepsis, coagulopathy, and/or
incomplete resuscitation. Altogether, the need for early resuscitation methods is critical.
Treatment with blood products may not always be available or the right course of treatment for
patients. Ensuring providers have all the necessary information when making treatment decisions
is essential, and the reviewed trials provide insight on optimal care. Individual patient profiles
were examined to determine the effectiveness of colloids. The discussion of what fluid is most
suited for patient treatment has been controversial considering the main goal of IV fluids is to
expand intravascular space. The main discussion that is occurring within the medical community
is what is the safety and efficacy of fluids in resuscitation. Thus, comparing the long-term patient
outcomes is essential in determining treatment plans. The fluids that are considered colloids are
albumin, h dro

eth l starch and gelatin. Lactated Ringer s and normal saline (sodium chloride)

are considered crystalloids. These colloid and crystalloid fluids were given in the reviewed trials.
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Function of Colloids and Crystalloids
Crystalloids have several different compositions and can respond differently within the
body based on its biochemical structure. Crystalloids that contain sodium and chloride are watersoluble electrolytes and lack proteins that make the molecules insoluble within the body.
Crystalloids containing sodium and chloride can be isotonic meaning the fluid can contain the
same balance and number of electrolytes as the plasma, hypertonic meaning the fluid contains
more electrolytes than the plasma, or hypotonic meaning the fluid contains less electrolytes than
the plasma. Other compositions such as Ringer s lactate contain sodium chloride, along with
sodium lactate, potassium chloride and calcium. Due to Ringer s lactate cr stalloids having
additional elemental components, Ringer s lactate cr stalloids are used to replace the fluid and
electrolytes with a patient that requires extra electrolyte composition. It should be noted, the
most common isotonic fluids do not cause water to shift between the extracellular fluid and the
intracellular fluid.2 A major disadvantage of crystalloids is the limited time the fluid remains
within the plasma. For example, when a patient is treated with a 1000mL bag of fluid, generally
up to 200 mL of that fluid is maintained within the vascular system and the rest is shifted into the
interstitial space.2
In contrast, colloids contain larger insoluble molecules than those of the crystalloid
compositions, which can include proteins, complex polysaccharides, albumins, starches, and
dextran. The larger molecules in colloids will not easily cross the capillary walls and remain
within the intravascular space for a much longer period than crystalloids, which is where the
benefit of colloid fluids are supposed to be derived.2 The theory is larger molecules in colloids
provide the ability to maintain a higher osmotic pressure for longer periods and are publicized as
the main purpose of colloid fluids.
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HES is a colloid composed of three hydroxy ethylated starches dispersed into a solution
of water and salts. HES has two main different compositions HES 200/0.5 and HES 130/0.4, the
first number represents the molecular weight and the second the ratio of substitution. The
metabolism of HES is through endogenous amylase, which will break down the starch molecules
(Figure 1). Next, the broken-down starch molecules will be filtered within the glomerulus and
excreted into the urine. Considering the substitution ratio of the fluid being applied is extremely
important. The substitution ratio is the determination of how slow or fast the molecules will
degrade within the vascular system. The higher the substitution ratio is the longer the molecules
will remain in the bloodstream, which in turn should require less fluids needing to be given to
patients over the time of resuscitation. The usage of colloids has been tested in patients suffering
from sepsis and will be discussed.
Colloid Usage in Sepsis
Despite more than 20 ears of intense therapeutic investigation, mortalit from septic
shock has remained at approximately 40-50%.

1

Utilizing fluid resuscitation is a mainstay in the

management of severe sepsis and septic shock. Inadequate initial treatment and dela ed
hemodynamic stabilization may be associated with increased risk of death in patients with severe
sepsis. 3 Overall early fluid resuscitation is a major step in the management of severe sepsis and
leads to improved prognosis. Optimi ed management in the first 6 hours has been reported to
significantly reduce mortality in patients with severe sepsis and septic shock.

3

Choosing the

right fluid might be the deciding factor to shift the balance in the patient's favor. Providers must
weigh the risk and benefits of all the fluids, including risks of acute kidney injury, increased
bleeding, and allergic reaction/anaphylaxis. The main question that needs to be answered is what
fluid is best in the treatment of sepsis and septic shock? This is a question that has been
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researched over several clinical trials over the past few years. The reviewed studies provide
insight into patient management and assist providers in selecting the proper fluid given the
patient profile. Relevant studies involving sepsis and fluid management examined below as part
of the overall review.
Assessment of Hemodynamic efficacy and safety of 6% Hydroxyethyl starch 130/0.4 vs.
0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study was doubleblind, randomized, controlled multicenter study conducted throughout 24 different medical
centers in France and three medical centers within Germany. One hundred patients were
randomized to be treated with Hydroxyethyl starch (HES) and 96 patients were randomized to a
control group with NaCl. When selecting patients, the origin of sepsis was noted and can be
found within Table 1. Most patients selected had a prevalence of sepsis within the lungs and
abdomen. There were no significant differences between treatment groups in demographic and
baseline characteristics.

4

The Simplified Acute Physiology Score II was used to evaluate

patients estimated mortality within the ICU. The authors found that there was no significant
difference in vital signs or hemodynamics within the two study groups. Patients within the study
received a maximum of 50 ml/kg/day on the first day and 25 ml/kg/day from the second to the
fourth day. The same formulary was used within both the HES and NaCl groups. It was noted
that if any fluid was required beyond the four-day time it was intravenous crystalloids with no
upper volume limit. Patients were followed for a total of 28 days and monitored for all-cause
mortality. To control for provider bias, the fluids were identical in appearance and packaging.
The study adequately controlled for biases and ensured the most thorough evaluation of fluids
was conducted. The study used well established protocols and was found to meet safety
standards by the French Independent Ethics Committee.
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The authors found in order to reach the desired hemodynamic stability significantly less
HES was used than NaCl (1,379 ± 886 ml in the HES group and 1,709 ± 1,164 ml in the NaCl
group [Mean difference = -331 ± 1,033, 95% CI -640 to -21], P = 0.0185).4 The time to reach
hemodynamic stability was an average of 2.5 hours shorter within the HES group, however these
findings were not found to be statistically significant (Table 2). The usage of HES during this
study did not induce AKI and the tubular or glomerular function was not affected (Table 3).
Urinar biomarkers of AKI were used as a ratio to urinar creatinine. The stud concluded that
there was no statistically significant effect on mortality when comparing HES and NaCl
treatment groups.

4

Therefore, the study found no major differences in mortality when

contrasting HES to NaCl.
In short, this study was one of two trials reviewed that found no major difference between
the need for renal replacement therapy when using HES over crystalloid for emergent
resuscitation. This is the only trial that found no difference between the need for renal
replacement with HES over crystalloid in sepsis. However, this has not been confirmed in larger
trials. In fact, the opposite was found in larger trials and HES and other colloids should not be
used within septic patients.
The next study evaluated is the Scandinavian Starch for Severe Sepsis / Septic Shock (6S)
trial, which was a large study conducted in 2009- 2022 throughout Denmark, Norway, Finland,
and Iceland. The trial was a blinded, parallel group with randomized patients (Table 4). A total
of 1211 patients were evaluated with 407 being excluded for the following reasons: 138
underwent renal-replacement therapy, 152 received >1000 ml of synthetic colloids, 51 consent
could not be obtained and 25 were already in another ICU trial. Consequently, 804 total patients
underwent randomization, where another 4 were excluded from the trial.5 Nonetheless, 400 were
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assigned to receive HES 130/0.42 and 400 were assigned to receive Ringer s Lactate. The trial
patients all fit criteria for severe sepsis according to the Society of Critical Care Medicine and
American College of Chest Ph sicians. The composite outcome measure of 90-day mortality or
end-stage kidney disease defined as dialysis-dependency 90 days after randomization will be the
primary outcome measure, and these two outcome measures will also be anal ed separatel .

5

Patients were followed up with at 6 month and 1 -year re-evaluation periods to assess for allcause mortality. The need for renal replacement therapy was followed for 90 days after
randomi ation. The fluids were visuall identical and were given in 500 ml fle bag plastic
bottles, which were put into black plastic bags to control for provider bias.
The primar outcome, death or dependence on dial sis at 90 da s after randomi ation,
occurred in 202 patients (51%) in the starch group as compared with 173 patients (43%) in the
Ringer s acetate group (relative risk, 1.17; 95% CI, 1.01 to 1.36; P = 0.03).

5

The P-value is

statistically significant and leads the researchers to conclude that patients with severe sepsis
receiving fluid resuscitation with HES had a higher risk of death at 90 days (Table 5). The
evaluated probability of survival using Kaplan-Meier analysis, which is a statistical tool that
measures the fraction of patients living after treatment, showed the survival time did not
significantly differ between the two groups (P=.07)(Figure 2). The patients within the colloid
group were more likely to have a need for renal-replacement therapy. The study found that 87
patients treated with HES required renal-replacement therapy, while only 65 patients treated with
Ringer s Acetate required renal-replacement therapy (relative risk, 1.35, 95% CI, 1.01-1.80;
P=.04. In short, this shows a statistically significant value when evaluating the relative risk.
Incidences of acute kidney injuries were found to have more than three points within the
Sequential Organ Failure Assessment score (SOFA), which means the patients would have a
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higher need for dialysis. The need for renal-replacement therapy, lengthens the time a patient
will require to stay within a healthcare facility; defined within the article as days alive outside of
the medical facility (Table 5). The mean days alive outside of the hospital was 29 with HES and
34 with Ringer s Acetate, which also increases a patient's risk profile. Patients being hospitalized
for a longer time can increase their mortality risk, due to iatrogenic causes. Within this study it
was found that less overall fluid would be required for a patient to return to hemodynamic
stability. The issues lie with the risk of using colloid fluids within the environment of severe
sepsis. Consequently, the data in the clinical trial argues that patients with severe sepsis should
not be treated with HES due to the increased mortality risk and dependency of renal replacement.
Colloid Usage in Treatment in Intensive Care Patients
The usage of intravenous fluids to increase intravascular volume is essential in treatment
of patients within intensive care units and emergency departments in saving lives around the
world. Globally, 0.9% sodium chloride (saline) is the most used fluid, although colloids were
administered almost as often as crystalloids with intensive care patients. HES is the most
frequently used colloid. Initially, colloid usage showed promise since colloids can safely and
efficiently provide fluid resuscitation. However, there is an increased risk of kidney injury when
using colloids.
Hydroxyethyl Starch for Fluid Resuscitation in Intensive Care (Chest) is a clinical trial
that was conducted from December 2009 through January 2012. The authors released a paper on
statistical analysis.6 Similarly, this trial was modeled after the Saline versus Albumin Fluid
Evaluation (SAFE) trial. The primary outcome was assessed from a standardized X 2 test
demonstrating the statistical significance of the treatment and monitored for 90-day all-cause
mortality. Cox proportional hazard model was utilized to obtain P-values and hazard ratio and
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was conducted by blinding the study-groups assignments within medical-surgical ICUs in
Australia and New Zealand. 7000 patients were enrolled through 32 different medical centers.
3500 patients were to receive 6% HES and 3500 were to receive 0.9% normal saline. The patient
eligibility can be seen in Table 6 in the appendix. Indistinguishable Free flex 500-ml bags were
used, which assisted in the blinding ensuring to reduce the provider bias. The study used a
ma imum of 50 ml per kilogram dosage of 6% HES (130/0.4). Independent anal sis of the
concentration and degree of molar substitution of HES and the concentration of saline was
obtained for a random sample of 20 bags with the use of gravimetric analysis and nuclear
magnetic resonance spectroscop (Chemical Anal sis).

6

The analysis of fluids allowed the

authors to ensure the fluids were properly prepared and uniform for use within the trial.
Controlling for the fluids was essential to ensure the removal of any additional variables from the
trial. Such as different fluid levels within the stud fluids. Stud treatments were randoml
assigned over an encrypted Web-based randomization system with the use of a minimization
algorithm stratified according to institution and an admission diagnosis of trauma.

6

If the

patients required more than the prescribed fluid amount, within the first 24-hour period, the
patients would be given 0.9% normal saline. All other aspects of care for the patients were
conducted at the discretion of the treating clinicians.
In the HES group, 597 of 3315 patients (18.0%) died within 90 da s after
randomization, as compared with 566 of 3336 patients (17.0%) in the saline group (relative risk
in the HES group, 1.06; 95% confidence interval [CI], 0.96 to 1.18; P = 0.26).

6

Therefore, there

was no significant difference in the primary outcomes of the study and there is no difference with
90-day mortality when comparing HES to normal saline. Despite the lack of difference in
survivability between HES and normal saline is a surprising result that has been replicated in
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subsequent trials. Even in the situation that HES was developed for, it did not have any effect on
overall survival. In conclusion, our study does not provide evidence that resuscitation with 6%
HES (130/0.4), as compared with saline, in the ICU provides an clinical benefit to the patient.

6

Once again, the issue with utilizing HES comes from the risk of acute kidney injuries to
the patients. Renal-replacement therapy was administered to 235 of 3352 patients (7.0%) in the
HES group and 196 of 3375 patients (5.8%) in the saline group (relative risk, 1.21; 95% CI, 1.00
to 1.45; P = 0.04).

6

Analysis was conducted to show that serum creatinine levels were

significantly increased within the HES groups. This increase in creatinine was seen initially and
grew exponentially over day one to three (Figure 3), while the urine output was slightly
decreased (Figure 4). The relative risk of the creatinine and urine-output components were
analyzed using RIFLE criteria. Both met criteria for kidney dysfunction (RIFLE-R) or within the
kidney injury (RIFLE-I). The use of HES led to an overall increased need for renal-replacement
therapy and was found to be statistically significant.
Additionally, the study noted an increased need for blood products with the patients
treated with HES and patients had a decreased rate of new cardiovascular failure. The Sequential
Organ Failure Assessment (SOFA) score was used to analyze results, which demonstrated a
reduced need for vasopressors in patients that were treated with HES. The decreased need for
vasopressors was attributed to the increased intravascular expansion of HES fluid resuscitation.
However, patients treated with HES showed an increase of treatment-related adverse events,
such as pruritus and skin rash. The adverse skin events occurred at a rate of 1.8 times higher
within the HES subgroups, with 169 patients having one of these adverse events. The normal
saline group only had adverse skin events occur within 87 patients. The findings of adverse skin
events are significant statistical findings with a P value of .006 (Figure 5). A possible cause of
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increased adverse skin events with HES groups could be caused by an accumulation in tissue,
specifically the reticuloendothelial system, which is manifested by pruritus with the potential of
leading to AKI and hepatic injuries.
In contrast to HES, the study A Comparison of Albumin and Saline for Fluid
Resuscitation in the Intensive Care Unit (SAFE) compared albumin to saline. The primary
outcome of trials was all-cause mortality at 28 days after inclusion into the trial. Also noting if
patients had any new organ failure. The study was double blinded, randomized and conducted
from 2001 to 2003 in 16 intensive care units across Australia and New Zealand. SOFA scores at
baseline were utilized and any higher scores were reported every day for seven days, followed by
tests every third day until discharged from the ICU or until the 28-day marker was reached.
Importantly, the need for mechanical ventilation, need of renal-replacement therapy, and length
of ICUs admissions were additionally noted.6 Of the 6997 patients selected for the trial, 3497
were assigned to receive albumin and 3500 to receive normal saline. Exclusion criteria for the
study included patients that underwent cardiac surgery, liver transplants and those undergoing
treatment for burns.6 The exact breakdown of patient characteristics upon admission into the
clinical trial can be seen in Table 7 in the appendix. Dissemination within the study consisted of
the colloid group receiving four percent albumin and crystalloid group receiving normal saline.
The study was blinded and used identical masked cartons, however, the fluid amount and rates
were determined by the treating providers and not chosen by the study investigators. The study
investigators utilized George Institute for International Health at the University of Sydney, a
secondary independent agency to assess the data analysis and manage the data collected.
When comparing the primary outcomes, there were 726 deaths in the albumin group and
729 in the saline group. (relative risk, 0.99; 95% CI, .097 to 1.09; P = 0.87).6 When assessing for
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new organ failure using the SOFA scores there was no significant difference. A Fischer s e act
test was utilized to reach a P-value of 0.85. The need for renal-replacement therapy was
statistically non-significant (relative risk, 0.09; 95% CI, 0.0 to .19; P = 0.41), meaning there was
no difference in the need for renal-replacement therapy between the two groups.
Conversely, the results from this clinical trial refute findings from a previous clinical
trial, Crystalloids vs. colloids in fluid resuscitation: a systematic review and was conducted in
1999, which reports patients that were treated with albumin in the ICU had a higher all-cause
mortality.6 Conversely, the results from this clinical trial refute findings from a previous clinical
trial that reports patients that were treated with albumin in the ICU had a higher all-cause
mortality. This previous study was Crystalloids vs. colloids in fluid resuscitation: a systematic
review and was conducted in 1999.6 Additionally, the results refute the evidence put forth by the
Cochrane Injuries Group Albumin Reviewers meta-analysis, which suggested that there would
be an increase in mortality if patients were treated with albumin during resuscitation. 15 However,
the trial did show evidence in patients that were suffering sepsis having a lower all-cause
mortality when treated with albumin, but this was not a specific outcome within the study (Table
7). Nonetheless, the results showing lower all-cause mortality with albumin treatment could be a
result of chance, so further studies into the specifics would be needed to confirm outcome
causation.
Colloid Usage in Hypovolemia
Hemorrhage accounts for up to 40% of trauma-related deaths.7 Restoring end-organ
perfusion and tissue oxygenation must be attained within a short time to reduce mortality. Most
of the mortality occurs within 6 hours after injury and this critical time is where selecting the
right fluid becomes essential.7 Colloid usage within hypovolemic patients has not been nearly as
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controversial. Colloids are regularly utilized within the United States and abroad for volume
resuscitation.
Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill
patients presenting with hypovolemic shock (CRISTAL), was a study conducted in February
2003 to August of 2012. Patients were selected from 57 different ICUs in France, Belgium,
Canada, Algeria, and Tunisia. Initially, 6498 patients were assessed for eligibility, while only
2857 were selected due to exclusion criteria. Patients were randomized into a colloid group and a
crystalloid group, 1414 to colloids and 1443 into crystalloid groups, respectively.8 To be
included in the CRISTAL study the patient must meet the following criteria for hypovolemia.
require fluid resuscitation for acute h povolemia as defined b the combination
of (1) hypotension: systolic arterial pressure of less than 90 mm Hg, mean arterial
pressure of less than 60 mm HG, orthostatic hypotension (i.e., a decrease in systolic
arterial pressure of at least 20 mm Hg form the supine to the semi recumbent position), or
a delta pulse pressure of 13% or higher; (2) evidence for low filling pressures and low
cardiac index as assessed either invasively or noninvasively; and (3) signs of tissue
hypoperfusion or hypoxia, including at least 2 of the following clinical symptoms: a
Glasgow Coma score of less than 12, mottled skin, urinary output of less than 25 mL/h or
capillary refilling time of 3 seconds or longer; and arterial lactate levels higher than 2
mmol/L, blood urea nitrogen higher than 56 mg/dL, or a fraction excretion of sodium of
less than 1%.8
The patients were not supposed to receive any fluids prior to admission into the clinical
trial, most patients excluded were due to receiving fluids prior to admission. The other exclusion
criteria encompassed anesthesia related hypotension, chronic liver disease, chronic renal failure,
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or acute anaphylactic reaction.8 A computer-generalized list was utilized with a fixed-block
permutation, which randomized patients into a 1 to 1 ratio. The crystalloid group could use any
hypertonic saline, isotonic solution, and buffered solutions.
The study allowed for usage of several different colloids, to include hypo-oncontics such
as gelatins and albumins and hyperoncotics such as dextrans, hydroxyethyl starch and 20% or
25% albumins. The different treatment groups could select whatever fluid that was available
within the facilities with the only restriction set within the colloid group to limit the dosage of
hydroxyethyl starch to no more than 30ml/kg of body weight. Moreover, the providers were
required to follow any local regulations set for usage of these fluids. Unlike previous studies
discussed above, the study advisors did not deem it possible to blind the clinicians to the fluid
interventions. Due to the interventions lasting throughout a patient s time within the ICU, it
would not be possible to provide enough masked fluids solutions for adequate resuscitation and
completion of the study. Instead, the investigators, sponsors, and members of the monitoring
board were blinded when statistical analysis was conducted. The primary outcomes of this study
were mortality at 28-days.
Importantly, the median fluid administered for the first week was 2000 mL of fluids with
the patients in the colloid group and 3000 mL of fluids in the crystalloid group. When assessing
the primary outcome of mortality at 28-days, the study concluded that there was no significant
difference. There were 359 deaths in the colloid group and 390 deaths within the crystalloids
group (RR, 0.96 [95% CI, 0.88-1.04], P=0.26).1 Surprisingly, this study showed there was no
difference in the need for renal replacement therapy when comparing the two different types of
fluids of colloids and crystalloids.
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During the study there were 156 patients in the colloid group and 181 patients in the
crystalloid group that identified a need for renal replacement, which was not found to be
statistically significant.8 The discrepancy in renal replacement needed compared to other studies
could be due to other studies focused more on HES than multiple different colloids and the fact
that the dosage of starches never exceeded the dose recommended by regulatory agencies.8 Be
that as it may, there was a significant difference in the mortality at 90-days for colloids vs
crystalloids, showing 434 deaths in the colloid groups and 493 deaths in the crystalloid
groups(RR 0.92 [95% CI,0.86 -0.99], P=.03).8 Conversely, there was a significant difference in
mortality noted within the colloid and crystalloid study groups, which need further exploration to
reach a conclusion of efficacy. Furthermore, resuscitation with colloids can be associated with
faster removal of life-support, which was exhibited by the mean number of days being alive
without mechanical ventilation within the colloid group being significantly lower. (Mean
difference, 1.10 [95% CI, 0.14-2.06], P=0.01). The results from this clinical study were limited,
due to the study outcomes and short timeframe of patients being tracked. Consequently, a
statistically significant difference was found between the average base excess serum after fluid
therapy (Figure 6) with a P-value of .001.8
Comparison of the Effectiveness of Hydroxyethyl Starch (Voluven) Solution With Normal
Saline in Hemorrhagic Shock Treatment in Trauma (VOLUVEN Trial) was conducted in 2016 at
Imam Khomeini Hospital in Ahvaz, Iran consisting of 100 initial participants. A total of 12
patients were excluded due to death, blood transfusion, or transference to an operating room. The
colloid group received .5 L of colloid solution with 1.5 L of normal saline and the crystalloid
group received 2 L of normal saline. This stud s approach was unique in the fact that the stud
utilized a calculation of base excess status when comparing crystalloid vs colloids. The primary
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outcome of the clinical trial was established by measuring the base excesses before and after
fluid therapy by drawing of ABG samples, 1 hour after administration.9 Outcomes were
calculated by utilizing covariance analysis and linear methods.9 This stud s approach was
unique in the fact that the study utilized a calculation of base excess status when comparing
crystalloid vs colloids. The primary outcome of the clinical trial was established by measuring
the base excesses before and after fluid therapy by drawing of ABG samples, 1 hour after
administration.9 Outcomes were calculated by utilizing covariance analysis and linear methods. 9
Colloid Usage in Burn Resuscitation
To treat burns in an acute setting requires a large amount of fluid resuscitation. Fluid
resuscitation in burn patients is essential to effectively reduce mortality and lead to improved
outcomes. The inflammatory response that occurs during burns can surpass that seen with trauma
and sepsis patients.10 Large fluid shifts that occur in severely burned patients with delaying, or
inadequate resuscitation can cause hypovolemia, tissue hypoperfusion, shock and organ failure.
Currently the fluid of choice for resuscitation is Lactated Ringers. The current Parkland
formulary can underestimate the actual fluid required for resuscitation.10 However, the Parkland
formula excludes the usage of colloids within the first 24 hours of fluid resuscitation. The initial
assumption is if colloids were used within fluid resuscitation the colloid would leak across
capillaries and exert osmotic pull, which could draw more fluid into the interstitial spacing.
Nevertheless, the fear of colloid leakage is unsubstantiated and is reviewed in Comparison of the
Effectiveness of Hydroxyethyl Starch (Voluven) Solution With Normal Saline in Hemorrhagic
Shock Treatment in Trauma. The increase in fluid resuscitation can correlate with an increased
intra-abdominal pressure and abdominal compartment syndrome. Colloid usage has shown to
help limit the overall volume needed to reach hemodynamic stability and reviewed in

Colloids Vs. Crystalloids 19

Hydroxyethyl starch supplementation in burn resuscitation—A prospective randomized
controlled trial.
The clinical trial Hydroxyethyl starch supplementation in burn resuscitation—A
prospective randomized controlled trial was conducted May 2004 to May 2006 at University
Hospital Birmingham Burns Centre in the United Kingdom. Patient inclusion criteria constituted
having burns exceeding 15% of total body surface area (TBSA) excluding those that had a 80%
TBSA, were pregnant, or had a delay of transfer greater than 6 hours from the time of injury.11
The Lund & Browder chart was employed for estimation of body surface area burned, this was
confirmed by two members of the staff.11 A block randomization was chosen to distribute the
patient allocation incoherently in the trial. The study began with 43 patients and only concluded
with 26 patients that completed the fluid trial and used for data analysis. The crystalloid group
was given Hartmann s solution according to the Parkland formula, which is the normal practice
for local hospitals. Meanwhile, patients selected for the colloid group received two-thirds
resuscitation of Hartmann s solution and one-third of the fluid replaced with 6% HES, with max
dosing of HES of 33ml/kg for 24 hours. However, the maximum dose given would not allow for
the full one-third to be replaced with HES. Instead the maximum allowed volume of HES was
infused at a regular rate and halved at 8 hours post-injury.11 The e pansive value of 6% HES is
in the region of 1:1.5, which means the blood volume expansion is achieved is 1.5 times the
volume of HES infused. The total 6% HES hourly volume allowance was translated into its
crystalloid equivalent, by multiplying it by 1.5. The resulting volume was subtracted from the
predicted crystalloid requirement for the hour which provided the hourl Hartmann s volume to
be infused.

11

Fluid resuscitation was titrated by the following criteria: Urine output of .5-

1ml/kg/h in uncomplicated burns and 1-2 ml/kg/h in inhalation injury with mean arterial pressure

Colloids Vs. Crystalloids 20

>70 mm HG and heart rate <120bpm.11 The tracking of Albumin-creatinine ratio (ACR) was
used to indicate endothelial dysfunction between the two groups and was used to determine the
primary outcome for the clinical trial. ACR was utilized as a marker for capillary leakage and
overall edema within the patients. Out of the 43 originally selected patients 26 were allowed into
the trial (Table 10). The mean TBSA for the study was 27%.
The primary outcome was concluded that in supplementation of HES in burn patients,
HES allowed for smaller fluid volume requirement (Table 10) and less tissue edema within the
first 24 hours (Table 11). The fluid requirement was corrected for the TBSA of each patient
suffering burns. The results of lower median serum CRP at 48 hours is statistically significant
with a P-value of .0001 within the treatment group of colloids. The ACR measurement at 12
hours when factoring in TBSA with a P-value of .0310 was found to be significant, within the
treatment group of colloids. This reduction in serum CRP allowed the investigators to draw the
conclusion that with treatment addition of colloids to burn regiments, patients with burns can
benefit from treatment within the first 24 hours.11 Withal, none of the patients within the clinical
trial required renal-replacement therapy, which can be related to the reduced dosage of HES that
was highlighted above.
A Prospective, Randomized Evaluation of Intra-abdominal Pressures with Crystalloid
and Colloid Resuscitation in Burn Patients was conducted at burns center in California and
Pennsylvania in 2002 and published in 2005. To meet inclusion criteria, patients had to have at
least 25% TBSA with smoke inhalations or greater than 40% TBSA if no inhalation injury was
present. Patient randomization was conducted by predetermined order produced in groups of 10.
Patients assigned in the crystalloid group applied the Parkland formula for volume resuscitation.
Utili ation of Lactated Ringer s at a rate of 4 mL/ kg/%TBSA, first half over initial 8 hrs.12
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Patients assigned to the colloid group were given plasma and crystalloid combination. The
patients in the colloid group were initiated on a 24-hour goal of 2,000 mL of Lactated Ringer s
and 75 mL/kg of fresh frozen plasma (FFP).12 The FFP was titrated to maintain urine output
between 0.5 and 1.0 mL/kg/h12. The primary outcome was a measure of intra-abdominal pressure
(IAP) measured in mmHg, which is an indication of the threshold for intra-abdominal
hypertension.
Conditions where fluids given were substituted with colloids such as FFP, a reduction
could be observed in the overall amount of fluids required for resuscitation and reduce the
overall occurrence of abdominal compartment syndrome with inevitably serious complications.
There was a statistically significant rise within both groups in measured IAP. The crystalloid
group had a rise to a mean IAP of 32.5mm Hg, which showed an increase of 26.5 mm Hg.12 The
colloid group had a rise to a mean IAP of 16.4 mm Hg, which only increased by 10.6 mm Hg.12
Altogether, the IAP increase of the crystalloid and colloid groups had a statistically significant Pvalue of .0001. The patients within the plasma group were given less fluids overall throughout
study, averaging only .561 L/kg. This clinical trial showed a direct relationship in the amount of
fluid given to a patient and overall IAP.
A mere 31 patients reached the end of the trail, creating a major confinement for overall
data analysis. To fully test these numbers with a power of 80%, with a 10% difference in
survival, expecting a P-value of .05 would require an inclusion rate of over 900.12 The
investigator deemed full analysis unattainable, even if utilizing a large multi-institutional study.12
Without a study of significant magnitude being conducted, the outcomes could not be directly
confirmed.
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Methods
PubMed, Science Direct and UpToDate were specifically searched to find articles that
conducted trials on colloids, and additionally explored articles that conducted trials where
providers compared colloids to crystalloids directly. The keywords utilized within the search
were colloid, cr stalloids, emergenc , resuscitation, burns, mortalit , shock, burns and sepsis .
Search criteria included peer-reviewed articles and clinical trials within the past 16 years. Of the
70 articles and clinical trials reviewed, 7 clinical trials and 13 articles were selected. These were
selected for their relevance to the topic, timing of clinical trials conducted and impact on
regulations for colloid usage. Several of the articles were selected for their direct reference in
FDA and European guidelines.
Discussion
Providers utilizing IV fluids for resuscitation to critically ill patients want to provide the
treatment with the best possible outcomes. The goal of this paper is to address if colloids usage
would allow for improved outcomes. Several conclusions can be drawn from the research and
will be discussed in each of the critically ill settings: including sepsis, hypovolemia, and burns.
Additionally, the studies reviewed have limitations that are addressed.
Patients suffering from sepsis or septic shock were reviewed within the CRYSTMAS and
6S clinical trial. These trials show conclusive evidence against the usage of colloids within
patients suffering sepsis. Both studies used HES in place of the colloid. The CRYSTMAS study
chose to utili e normal saline, while the 6S chose to give Lactated Ringer s. This difference in
crystalloid selection had very little to no impact on the outcomes of the clinical trial. In the
CRYSTMAS and 6S clinical trial found no difference in mortality in septic patients. However,
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there was a difference in the two trials when comparing the need for renal replacement therapy.
In the CRYSTMAS trial the investigators found no statistically significant difference in the need
for renal replacement when comparing colloid vs crystalloids. The 6S clinical trial found a
statistically significant difference in the need for renal replacement when comparing colloids to
crystalloids. These differences could be due to the limitation within the CRYSTMAS study. The
CRYSTMAS study had a small patient population. This limited population size can lead to
unreliable findings and not provide a full picture when comparing the two fluids. The main
limitation within the CRYSTMAS study was the overall purpose of the study was not assessing
the mortality, but focused on which IV fluid would allow a patient to reach hemodynamic
stability fastest. One factor that could have affected the findings in the 6S clinical trial was the
inclusion of patients that had AKI prior to application of the fluids. The inclusion of patients
suffering from AKI could have affected the data and patient need for renal replacement therapy.
As these patients suffering from AKI already have kidney dysfunction and could have led to the
increased need for renal replacement therapy. Even with these limitations, there is no difference
in mortality when treating patients with colloids vs crystalloid. Colloids have the increased risk
of acute kidney injury in sepsis making the fluid benefit not worth the risk.
Hypovolemia and hypovolemic shock were tested within the CRISTAL and the
VOLUVEN clinical trials. The outcomes of the CRISTAL study were tracking mortality and the
need for renal replacement. Within the VOLUVEN clinical trial the outcome was not following
mortality but calculating the base excess status when comparing crystalloids vs colloids. The
findings of this clinical trial indicated that colloids are superior to crystalloids if properly
administered to patients in hypovolemia and hypovolemic shock. This is most apparent in the
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CRISTAL trial where the authors found a significant difference in mortality supporting colloids
vs crystalloids.
There was some limitation within both clinical trials. The CRISTAL clinical trial was
running over a period of 9 years. This is a long time to run a study and could prove difficult to
maintain consistency in treatment protocols within the medical facilities. There was no mention
if the trials controlled for these changes. There was no blinding of fluids within either the
CRISTAL or VOLUVEN trials. These trials noted that it was not feasible to blind the fluids. The
CRISTAL trial did note a chance of bias, but the authors refuted the claim b stating, this would
have likely resulted in an increased use of renal replacement therapy in patients treated with
colloid.

8

The CRISTAL trial showed no significant difference in the need for renal replacement

therapy when comparing crystalloid and colloids. Within the VOLUVEN clinical trial there was
a much smaller patient cohort. Without adequate data points it can lead invalid data overall. The
authors did not track mortality, but instead collected data on base excess status when comparing
crystalloids to colloids. Other crucial sepsis indicators such as lactate were not collected.
Burn treatment with colloids was tested within clinical trials A Prospective, Randomized
Evaluation of Intra-abdominal Pressures with Crystalloid and Colloid Resuscitation in Burn
Patients and Hydroxyethyl starch supplementation in burn resuscitation—A prospective
randomized controlled trial. These clinical trials did show some compelling evidence for the
usage of colloids within burn patients. There were several limitations within both clinical trials.
The two clinical trials used completely different colloids. One utilizes FFP and the other used
HES. This difference in types of colloids used could lead to changes in the results from each
study. Both clinical trials were hindered by the number of patients within the cohort, which can
lead to issues with validity in the outcomes of the clinical trials. Additionally, it is almost
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impossible to completely control differences in full thickness burns between the control and
study group. However, the investigators attempted to control for this by changing the fluid
calculation and ACR. This was noted to be a valid control but having different thicknesses and
locations of burns can affect the results.
Conclusion:
In emergent resuscitation, efforts in the setting of sepsis, hypovolemia and burns, a
provider has the options of colloids or crystalloids. This paper evaluated the effectiveness of
colloids and crystalloid fluids to compare the outcomes of mortality. In the setting of sepsis,
there is not enough evidence to support the usage of colloids. Several studies conducted show no
decrease in mortality. This includes the CRYSTMAS and 6S clinical trial that showed no
decrease in mortality in patients presenting in severe sepsis. The amount of fluid resuscitation
needed by patients in sepsis is massive. Confirmed by the CRYSTMAS and 6S, the need for
patients to undergo renal replacement therapy after resuscitation with colloids is a definite risk if
the patients are in severe sepsis or septic shock. Acceptedly, during the clinical trials reviewed,
colloid usage should not be used within sepsis and septic shock. There is little debate on
restricting colloid usage in terms of septic patients. The medical community and guidelines have
been established within the United States and the European union. These guidelines have
established treatment protocols that restrict the usage, and these are supported by the findings
within the CRYSTMAS and 6S clinical trials.
Importantly, there is evidence to support the usage of colloids within hypovolemia, but
some restrictions that must be placed on its usage. Several studies have come out to show that
HES should not be used due to increased risk of AKI (CRYSTMAS and 6S). However, the trials
were tested in a population with signs of sepsis and septic shock, so should not be considered as
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direct results for treatment of hypovolemia. Albumin does seem to show promise if utilized
appropriately with a combination of crystalloid. Demonstrated, the risk of renal-replacement
therapy can be mitigated with lower doses of HES and colloids. During the larger CRISTAL
trial, the results illustrated no increased need for renal replacement therapy and showed a
reduction in all-cause mortality at 90 days. Authors noted an inherent need for more studies to be
conducted to support finding of reduced renal replacement therapy need and reduction of
mortality due to not being the direct outcome being tested. Altogether, the large-scale study
allowed HES or other colloid usage to be recognized for faster patient recovery by manifesting a
significantly lower mean number of days alive without mechanical ventilation within the colloid
group. Nonetheless, the results of the clinical trials do not directly support the fear of using HES
or other colloids in hypovolemic shock. More studies are required with restricted dosages to
verify if HES does cause a need for renal-replacement therapy. Once additional study has been
conducted on restricted HES dosages, there is potential for a shift within treatment protocols. As
it currently stands, most treatment protocols forgo the usage of colloids, specifically HES in any
circumstances. Even though HES may never become as utilized or as effective as initial claims,
HES could have a purpose when used in a more restrictive and isolated environment.
Colloids usage within burns has not been extensively studied in larger multi-institutional
studies in recent years. There is evidence that colloids can be effective within burn patients in the
right circumstances. However, several smaller studies show promising results using either HES
or plasma for substitution in fluid resuscitation. Results demonstrating colloid usage in burns can
be seen within Hydroxyethyl starch supplementation in burn resuscitation—A prospective
randomized controlled trial and A Prospective, Randomized Evaluation of Intra-abdominal
Pressures with Crystalloid and Colloid Resuscitation in Burn Patients. Promise is shown with

Colloids Vs. Crystalloids 27

colloid fluids, whether using references of IAP or measures of ACR for endothelial dysfunction.
The ability for providers to reduce the amount of crystalloid usage by an addition of colloid
could lessen the impact of resuscitation needed in burn patients. Even so, ensuring providers set
clear goal directed recitation is essential. Within the article Fluid resuscitation Management in
patients with burns: update discusses the following:
Although there are reports of poorer outcomes in septic patients with the use of HES, the
current scientific evidence does not suffice to support a specific contraindication for HES
use in burn patients. As was the practice in many burn units, we formerly used HES after
the first 24 h when it was needed and we did not have the impression that outcomes were
worse in our patients, but this is a subjective evaluation.13
Several of the meta-analysis referenced that burn patients should not be given HES. In some of
the larger studies burn patients were excluded from the studies. Then clinicians use these studies
that excluded burn patients to draw conclusions that HES should not be given.
There needs to be a more in-depth clinical trial when utilizing colloids in early burn
management as the studies Hydroxyethyl starch supplementation in burn resuscitation—A
prospective randomized controlled trial and A Prospective, Randomized Evaluation of Intraabdominal Pressures with Crystalloid and Colloid Resuscitation in Burn Patients show validity
in colloid usage. The article Fluid resuscitation Management in patients with burns: update
discusses the following:
Multicenter randomized controlled trials on fluid resuscitation in major burns are still
needed to define the best fluid therapy in this population. Data is lacking on the optimal
end points for TTD, the difference between initial resuscitation with Ringer's lactate or
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Ringer's acetate, the proper timing to initiate colloids, and the comparative performance
of the different natural and synthetic colloids in burn patients.13
It has been concluded, healthcare providers should not use HES in patients in sepsis,
kidney impairment, or in critically ill patients, and restricted use of HES is supported by the
European Union of the Coordination Group for Mutual Recognition and Decentralized
procedures- Human- and by the FDA in the United States. However, HES is supplied to EU only
accredited hospitals for use, but specific training is required for the safe use of HES solutions.
For safety, specific warnings on the packaging and the top of the product illustrate that HES
medicines should not be used in patient profiles with sepsis, kidney impairment, or in critically
ill patients.14 An additional added contraindication included severe coagulopathy, which was not
discussed within this paper and HES must be discontinued at the first sign of coagulopathy.
Additionally, HES solutions for infusion are contraindicated in dehydrated patients,
hyperhydrated patients, patients with intracranial or cerebral hemorrhage, burn injuries, severe
hyperkalemia, hypernatremia, hyperchloremia, congestive heart failure, organ transplant patients
and patients with impaired hepatic function.14 However, some of the contraindications are not
confirmed risks within clinical trials, such as burns.
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Appendix
Figure 1. Hydroxyethyl Starch molecule with the action of amylase

Table
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1. Patient Demographics and baseline characteristics for patient in the CRYSTMAS study

Table 2: Efficacy outcomes during the CRYSTMAS study
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Table 3: Urinary Biomarkers of AKI as a ratio to urinary creatine within the CRYSTMAS Study.

Table 4: Patient selection for 6S clinical trials.
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Table 5: Primary and secondary results from the 6S clinical trial
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Figure 2: Kaplan-Meier anal sis for the patient s probabilit of survival within the 6S clinical trial.
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Table 6: Patient eligibility for the CHEST clinical trial
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Figure 3: Serum Creatine in patients during the CHEST clinical trial

Figure 4: Urine output in patients during the CHEST clinical trial
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Figure 5: Patient outcomes and adverse events within the CHEST clinical trial
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Table 7: Baseline Characteristics of Patient within the SAFE clinical trial
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Table 8: Paitient enrollment within the CRISTAL clinical trial

Table 9: Outcomes by treatment group CRISTAL clinical trial
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Figure 6: Base Excess changes Comparison of the Effectiveness of Hydroxyethyl Starch (Voluven) Solution
With Normal Saline in Hemorrhagic Shock Treatment in Trauma clinical trial

Figure 7: Patient recruitment for burns fluid resuscitation in Hydroexyethylstarch supplementation in
burn resucitation

Table 10: Resucitation Fluid date for Hydroexyethylstarch supplementation in burn resuscitation clinical
trial
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Table 11: Inflammatory marker data for Hydroxyethylstarch supplemetnation in burn resucitation clinical
trial

Table 12: Peak results and findings for A Prospective, Randomized Evaluation of Intra-abdominal
Pressures with Crystalloid and Colloid Resuscitation in Burn Patients

